Develops a light-activated compound that destroys cancer cells without damaging healthy tissue.
| Date | Round | Amount |
|---|---|---|
| Jun 2025 | Pre Seed GenLumina received proof-of-concept capital from the UNIIQ fund to set up an experimental laboratory for its light-activated cancer therapy. | — |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.